September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
FDA Clears First-Ever OTC Glucose Sensor: Dexcom Stelo Glucose Biosensor System
The Dexcom system is for adults over the age of 18 years who do not use insulin, such as individuals with T2D who use oral medications, a US population of 25 million.
Two Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court
Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.
Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced
Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.
Rapid Progression of CKD Can Be Detected Early Using Simple Markers in Primary Care
The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.
Global Obesity Rates Top One Billion, Quadrupling Among Youth from 1999-2022
Obesity rates in the US over the 3 decades rose from 11.5% to 21.7% among boys and from 11.6% to 19.4% among girls. US men ranked 10th highest for obesity in 2022.
Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data
Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.
Viking Therapeutics Dual GIP/GLP-1 Mimetic Drives Weight Loss of Up to 14.7% in Phase 2 Findings
Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.
Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
Lowering Out-of-Pocket Rx Costs May Improve Diabetes Outcomes: Daily Dose
Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Persons with T2D, NAFLD: Daily Dose
T2D Remission After Gastric Bypass Persists, Despite Weight Regain
People with T2D and obesity who had gastric bypass surgery maintained significant levels of disease remission, despite up to 100% weight regain, study finds.
Tighter Glycemic Control in Type 2 Diabetes May Reduce Risk for All-Cause Dementia: New Findings
Comprehensive management of T2D in primary care settings reduced risk of all-cause dementia by 28%, with lower HbA1c linked to lower, but still elevated risk.
Reducing Out-of-Pocket Rx Costs May Help Improve Diabetes Outcomes, Particularly for those with Lower Incomes
Acute, preventable diabetes complications days fell by 8.4% among participants enrolled in a preventive drug list benefit and by even more among low-income subscribers.
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Patients with T2D and NAFLD, According to New Research
Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.
Tirzepatide Linked to “Impressive” BP Reduction in Adults with Obesity: Daily Dose
Novel Weight Loss Entrant from Amgen Challenges Duration of Effect and Dosing with Wegovy, Zepbound
Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.
Risk for a Suicide Attempt Found 8-Fold Greater in Women with PCOS
Among women with PCOS, the risk for a suicide attempt was highest (by a factor of 9) among young adults aged 20 to 40 years, followed by adolescents.
Tirzepatide Associated with "Impressive" BP Reduction in Individuals with Obesity
Mean placebo-adjusted SBP change from baseline at 36 weeks was 8.6 mm Hg in adults with obesity, according to authors of the SURMOUNT-1 ABPM substudy.
HbA1c Greater than 6.0% Raises T2D Risk in Children with Obesity: Daily Dose
Daily Dose: Childhood Stress & Risk for Cardiometabolic Disease
Baseline HbA1c Greater than 6.0% Linked to "Exponential" Increase in T2D Risk for Adolescents with Obesity
Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.
FDA Adds Black Box to Prolia PI Warning of Severe Hypocalcemia Risk in CKD
The Boxed Warning reflects FDA research into severe adverse events including hospitalization and death in persons with CKD treated with denosumab.
Diabetes Remission of Any Duration May Reduce Risk of Renal and Cardiovascular Disease:
Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.
Newly FDA-Authorized Diabetes Digital Therapeutic Can be Cost-Effective, According to Modeling Study
The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.
Where is All the Wegovy Going? Highest and Lowest Prescribing States
The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.
Daily Dose: Semaglutide Not Linked to Suicide Ideation
More Childhood Stress Linked to Increased Risk for Cardiometabolic Disease
Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.
Daily Dose: NAFLD Associated with Adverse Outcomes Regardless of BMI
FDA Review Suggest No Link Between GLP-1RAs and Suicidal Thoughts but Surveillance Will Continue
While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.